Filing Details
- Accession Number:
- 0001179110-18-009761
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-17 17:30:43
- Reporting Period:
- 2018-07-13
- Accepted Time:
- 2018-07-17 17:30:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1733094 | Young Kwon | C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142 | Svp, Corporate Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-07-13 | 11,000 | $13.26 | 136,624 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 11,000 | $27.40 | 125,624 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-07-13 | 8,000 | $15.44 | 133,624 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 8,000 | $27.40 | 125,624 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-07-13 | 6,000 | $12.58 | 131,624 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 6,000 | $27.40 | 125,624 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-07-13 | 6,000 | $17.96 | 131,624 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 6,000 | $27.48 | 125,624 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-07-13 | 3,500 | $13.02 | 129,124 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 3,500 | $27.33 | 125,624 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-07-13 | 4,000 | $21.56 | 129,624 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-07-13 | 4,000 | $27.40 | 125,624 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-07-13 | 11,000 | $27.35 | 114,624 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 11,000 | $0.00 | 11,000 | $13.26 |
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 8,000 | $0.00 | 8,000 | $15.44 |
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 6,000 | $0.00 | 6,000 | $12.58 |
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 6,000 | $0.00 | 6,000 | $17.96 |
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 3,500 | $0.00 | 3,500 | $13.02 |
Common Stock | Stock Option(Right to Buy) | Disposition | 2018-07-13 | 4,000 | $0.00 | 4,000 | $21.56 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
19,500 | 2015-02-22 | 2021-02-22 | No | 4 | M | Direct |
8,500 | 2016-02-14 | 2022-02-14 | No | 4 | M | Direct |
10,800 | 2017-02-19 | 2023-02-19 | No | 4 | M | Direct |
13,986 | 2018-02-18 | 2024-02-18 | No | 4 | M | Direct |
22,225 | 2018-05-18 | 2025-02-18 | No | 4 | M | Direct |
14,000 | 2018-05-11 | 2025-08-11 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $26.90 to $27.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.